View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
September 29, 2020

FDA places partial hold on Inovio’s Phase II/III Covid-19 vaccine trial

The US Food and Drug Administration (FDA) has placed partial clinical hold on Inovio Pharmaceuticals' planned Phase II/III clinical trial of its potential Covid-19 vaccine, INO-4800.

The US Food and Drug Administration (FDA) has placed partial clinical hold on Inovio Pharmaceuticals’ planned Phase II/III clinical trial of its potential Covid-19 vaccine, INO-4800.

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

The regulator asked the company to provide more information on the trial, including details about the use of CELLECTRA 2000 delivery device.

Inovio would respond to FDA’s queries in October, after which the agency will have up to 30 days to decide whether the trial may proceed.

The company noted that the partial clinical hold was not due to any adverse events in the expanded Phase I study of the vaccine candidate, which is ongoing and will continue.

Phase I interim analysis showed that the product was generally safe and well-tolerated.

Inovio further said: “In addition, this partial clinical hold does not impact the advancement of Inovio’s other product candidates in development.

“Inovio and its partners are continuing to prepare for a planned Phase II/III trial of INO-4800, following resolution of the FDA’s partial clinical hold and subject to the receipt of external funding to conduct the trial.”

The company has formed alliances with a global coalition of collaborators, partners and funders to rapidly develop INO-4800 against Covid-19.

So far, its R&D collaborators include the Wistar Institute, the University of Pennsylvania, the University of Texas, Fudan University and Laval University.

The company has partnered with Advaccine and the International Vaccine Institute for trials of the vaccine candidate in China and South Korea, respectively.

Furthermore, the company is working with Public Health England (PHE) and Commonwealth Scientific and Industrial Research Organization (CSIRO) in Australia to test INO-4800’s non-clinical efficacy.

A team of contract manufacturers, including Thermo Fisher Scientific, Richter-Helm BioLogics and Ology Bioservices, are working to commercially produce the product.

Following funding from the Coalition for Epidemic Preparedness Innovations (CEPI), the Bill & Melinda Gates Foundation and the US Department of Defense, the company is seeking additional finance to support the INO-4800 project.

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena